Trial Profile
A RANDOMIZED, MULTICENTER, DOUBLE BLIND CLINICAL TRIAL COMPARING PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY OF A BIOSIMILAR EPTACOG ALFA (ARYOSEVEN) AND NOVOSEVEN, IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors AryoGen Pharmed
- 26 Apr 2023 This trial has been discontinued in Bulgaria (Date of the global end of the trial: 29 Sep 2021).
- 03 Feb 2021 Status changed from recruiting to completed.
- 07 Jan 2021 Planned End Date changed from 1 Nov 2020 to 25 Feb 2021.